{
  "document_id": "HOUSE_OVERSIGHT_028418",
  "filename": "IMAGES-009-HOUSE_OVERSIGHT_028418.txt",
  "text": "pitch its story to Wall Street. It settled on Mr. Hugin, a managing director at J.P.\n\nMorgan.\",\"type\":\"text\"}, {\"bannerType\"™:\"any\", \"identifier\":\" anf-banner advertisement\n5\",\"layout\":\"ComponentLayout-—\n4\",\"role\":\"banner advertisement\", \"type\":\"banner advertisement\"}, {\"additions\": [{\"URL™:\"h\n\nttps://bobhugin.com/about/\", \"range\": {\"length\":19, \"start\":176}, \"type\":\"link\"}, (\"URL\":\"ht\ntps://www.sec.gov/Archives/edgar/data/816284/000100515000000449/0001005150-00-\n\n000449.txt\", \"range\": {\"length\":21,\"start\":223},\"type\"™:\"link\"}],\"identifier\":\" anf-body-\n27\",\"inlineTextStyles\": [{\"range\"™:{\"length\":461,\"start\":0},\"textStyle\":\" anf-ts-\n\ni\"}, {\"range\"™:{\"length\":461,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-\nbody\", \"role\": \"body\", \"text\": \"At the time, the companyde€™s financial situation was\n\nperilous. Celgene had 200 employees and was getting by on less than six weeks of cash\nwhen Mr. Hugin joined, according to his campaign biography. A year later, the company\nwarned investors that, Aa€eduring the next several years, we will be very dependent on\nthe commercial success of Thalomid,d4€ while also acknowledging that the market for the\nonly disease for which the drug was approved was Aa€erelatively\n\nsmall.a€\",\"type\":\"text\"™}, {\"identifier\":\" anf-heading4-\n2\",\"layout\":\"heading4\", \"role\": \"heading4\", \"text\":\"Seeking a windfall by exploiting drug\nsafety rules\",\"type\":\"text\"}, {\"identifier\"™:\" anf-body-\n\n28\",\"inlineTextStyles\": [{\"range\"™:{\"length\":387,\"start\":0},\"textStyle\":\" anf-ts-\n\ni\"}, {\"range\"™: {\"length\":387,\"start\":0},\"textStyle\":\"_anf-ts-1\"}],\"layout\":\"default—\nbody\", \"role\": \"body\", \"text\":\"Drug companies are forbidden from promoting a drug for any\nunapproved uses, but doctors have broad discretion to prescribe a product for a range\nof diseases. Celgene appeared to exploit this distinction almost as soon as Thalomid\n\narrived on the market, according to company filings, public statements and internal\ndocuments included in the whistle-blower lawsuit Celgene settled in\n2017.\",\"type\"™:\"text\"}, {\"identifier\":\" anf-body-\n\n29\",\"inlineTextStyles\": [{\"range\"™:{\"length\":257, \"start\":0},\"textStyle\":\" anf-ts-\n\ni\"}, {\"range™:{\"length\":257,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-\nbody\", \"role\":\"body\", \"text\":\"The company hired a team of 60 sales representatives, many\nof whom had experience in oncology, according to financial filings, and just months\nafter Thalomid arrived on the market, Celgene announced that it would pursue F.D.A.\napproval for multiple myeloma.\", \"type\": \"text\"}, {\"components\": [{\"caption\":\"Mr. Hugin has\ndefended his role as a top executive at Celgene, saying that he helped lead a company\nthat developed life-saving medicines. Rick Loomis for The New York\n\nTimes\", \"captionComponent\": {\"text\":\"Mr. Hugin has defended his role as a top executive\nat Celgene, saying that he helped lead a company that developed life-saving medicines.\nRick Loomis for The New York\nTimes\"},\"identifier\":\"100000006098033 Sba8b804122ca\", \"imageldentifier\":\"c275d4ffab4cd56\n96e6a2645c43Ff84a0\", \"Layout\": \"fullbleed-\n\nimage\", \"role\":\"photo\", \"type\": \"scalable image\"}, {\"identifier\":\" anf-caption-\n3\",\"inlineTextstyles\": [{\"range\": {\"length\":35, \"start\":138}, \"textstyle\": \"photo-\ncredit\"}],\"layout\":\"default-caption\", \"role\": \"caption\", \"text\":\"Mr. Hugin has defended\nhis role as a top executive at Celgene, saying that he helped lead a company that\n\ndeveloped life-saving medicines. Rick Loomis for The New York Times\n\",\"type™:\"text\"}],\"identifier\":\" anf-container-2\",\"layout\"™:\"image-\n\ncontainer\", \"role\":\"container\", \"type\":\"container\"}, {\"additions\"™: [{\"URL\":\"http://wayback.\narchive-\n\nit.org/7993/20170112071439/http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulat\noryiInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPh\narmaceuticalCompanies/UCM167840. pdf\", \"range\": {\"length\":47,\"start\":100}, \"type\":\"Llink\"}, {\n\"URL\": \"https://www.washingtonpost.com/archive/politics/2000/05/05/fda-moves-to-curb\nads-for-thalidomide/dd6ce44a-711b-424c-a9a0\nae67168f170c/?utm term=.f0af824af352\", \"range\": {\"length\":16,\"start\":246},\"type™:\"Link\"}]\n,\"identifier\":\" anf-body-\n30\",\"inlineTextStyles\":[{\"range\": {\"length\":319, \"start\":0},\"textsStyle\":\" anf-ts-\n\ni\"}, {\"range™:{\"length\":319,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-\nbody\", \"role\":\"body\", \"text\":\"The F.D.A. reprimanded Celgene multiple times in those\nearly years, telling the company that it had not adequately warned about\nthalidomideade€™s risks in its announcement about multiple myeloma, and calling a meeting\nin December 1998 to warn of its Aa€estrong concernd€ that Celgene was marketing Thalomid\n\nfor unapproved uses.\",\"type\":\"text\"}, {\"bannerType”™: \"any\", \"identifier\"™:\" anf-\nbanner advertisement-6\", \"layout\": \"ComponentLayout—\n4\",\"role\":\"banner advertisement\", \"type\":\"banner advertisement\"}, {\"additions\": [{\"URL™:\"h\n\nttp://wayback.archive-\nit.org/7993/20170112070734/http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulat\noryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPh\narmaceuticalCompanies/UCM165843.pdf\", \"range\": {\"length\":41, \"start \":9},\"type™:\"link\"}],\"i\n\nHOUSE_OVERSIGHT_028418",
  "metadata": {
    "original_filename": "IMAGES-009-HOUSE_OVERSIGHT_028418.txt",
    "source_dataset": "huggingface:tensonaut/EPSTEIN_FILES_20K",
    "character_count": 5210,
    "word_count": 480,
    "line_count": 88,
    "import_date": "2025-11-19T21:47:46.999940",
    "prefix": "IMAGES-009"
  }
}